US Bancorp
RCKT icon

US Bancorp’s Rocket Pharmaceuticals RCKT Stock Holding History

US Bancorp’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.1K Sell
1,198
-626
-34% -$2.08K ﹤0.01% 3711
2026
Q1 		$6.53K Sell
1,824
-1,163
-39% -$4.62K ﹤0.01% 3494
2025
Q4 		$10.5K Buy
2,987
+2,040
+215% +$6.99K ﹤0.01% 3319
2025
Q3 		$3.09K Sell
947
-649
-41% -$2.04K ﹤0.01% 3676
2025
Q2 		$3.91K Buy
1,596
+182
+13% +$922 ﹤0.01% 3711
2025
Q1 		$9.43K Sell
1,414
-58
-4% -$573 ﹤0.01% 3455
2024
Q4 		$18.5K Buy
1,472
+620
+73% +$9.33K ﹤0.01% 3188
2024
Q3 		$15.7K Sell
852
-230
-21% -$4.71K ﹤0.01% 3212
2024
Q2 		$23.3K Sell
1,082
-1,095
-50% -$25.1K ﹤0.01% 3003
2024
Q1 		$58.6K Sell
2,177
-4,190
-66% -$119K ﹤0.01% 2607
2023
Q4 		$191K Sell
6,367
-3,194
-33% -$70.5K ﹤0.01% 2029
2023
Q3 		$196K Buy
9,561
+8,230
+618% +$150K ﹤0.01% 1840
2023
Q2 		$26.4K Buy
1,331
+113
+9% +$2.28K ﹤0.01% 2836
2023
Q1 		$20.9K Buy
1,218
+30
+3% +$587 ﹤0.01% 2963
2022
Q4 		$23.2K Sell
1,188
-91
-7% -$1.68K ﹤0.01% 2921
2022
Q3 		$20K Sell
1,279
-346
-21% -$5.4K ﹤0.01% 3019
2022
Q2 		$22K Sell
1,625
-8,659
-84% -$103K ﹤0.01% 3002
2022
Q1 		$164K Buy
10,284
+1,150
+13% +$19.9K ﹤0.01% 2041
2021
Q4 		$199K Buy
9,134
+1,344
+17% +$36.7K ﹤0.01% 1977
2021
Q3 		$233K Buy
7,790
+1,902
+32% +$69.2K ﹤0.01% 1904
2021
Q2 		$261K Buy
5,888
+811
+16% +$35.2K ﹤0.01% 1863
2021
Q1 		$225K Buy
5,077
+4,822
+1,891% +$265K ﹤0.01% 1873
2020
Q4 		$14K Buy
255
+142
+126% +$5.18K ﹤0.01% 3060
2020
Q3 		$3K Buy
+113
New +$2.78K ﹤0.01% 3437

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

US Bancorp's RCKT Position: Q2 2026 in Review

US Bancorp reduced its Rocket Pharmaceuticals (RCKT) stake by 34% in Q2 2026, selling an estimated $2.08K and leaving 1,198 shares worth $4.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3711.

US Bancorp first reported a position in RCKT in Q3 2020 and has held it in 24 quarters since. The position peaked at $261K in Q2 2021. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • US Bancorp held 1,198 shares of Rocket Pharmaceuticals worth $4.1K as of Q2 2026.
  • US Bancorp sold 626 Rocket Pharmaceuticals shares in Q2 2026, an estimated $2.08K.
  • Rocket Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3711 holding.
  • US Bancorp first reported a position in Rocket Pharmaceuticals in Q3 2020 and has held it in 24 quarters since.
  • US Bancorp's Rocket Pharmaceuticals position peaked at $261K in Q2 2021.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.